

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI,TDBD	Asahara-takayuki.in.	3	<u>L11</u>
USPT,JPAB,EPAB,DWPI,TDBD	Isner-jeffrey-m\$.in.	25	<u>L10</u>
USPT,JPAB,EPAB,DWPI,TDBD	Isner-jeffrey-k\$.in.	0	<u>L9</u>
USPT,JPAB,EPAB,DWPI,TDBD	L7 and (neoangiogenesis or vascularization)	3	<u>L8</u>
USPT,JPAB,EPAB,DWPI,TDBD	(GM-CSF) and (EPC or ((endothelial progenitor) adj cell))	22	<u>L7</u>
USPT,JPAB,EPAB,DWPI,TDBD	L5 and (GM-CSF or G-CSF or M-CSF)	8	<u>L6</u>
USPT,JPAB,EPAB,DWPI,TDBD	(therapeutic angiogenesis)	26	<u>L5</u>
USPT,JPAB,EPAB,DWPI,TDBD	L2 and (EPC? or angioblast)	2	<u>L4</u>
USPT,JPAB,EPAB,DWPI,TDBD	L2 and ((EPC) or (endothelial progenitor?))	1	<u>L3</u>
USPT,JPAB,EPAB,DWPI,TDBD	L1 and (GM-CSF or G-CSF or M-CSF)	66	<u>L2</u>
USPT,JPAB,EPAB,DWPI,TDBD	(therapeutic angiogenesis) or (neovascularization)	1558	<u>L1</u>

Set Name Query
side by side

*DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; THES=ASSIGNEE;
PLUR=YES; OP=AND*

L6 L5 and (ischemia)
L5 L4 and ((GM-CSF) or (M-CSF) or (b-FGF) or SCF or (SDF-1) or
(G-CSF) or HGF or angiopoietin or (FLT-3))
L4 ((endothelial adj progenitor) adj cell) or (EPC)
L3 Asahara-takayuki.in.
L2 L1 and (GM-CSF)
L1 Isner-jeffrey-M\$.in.

Hit Count Set Name
result set

8 L6
44 L5
2622 L4
4 L3
4 L2
23 L1

END OF SEARCH HISTORY

constitutive overexpression of VEGF sufficient to induce *therapeutic*
 angiogenesis in selected patients with critical *limb* *ischemia*.

MEDICAL DESCRIPTORS:

**limb* *ischemia*--therapy--th; *gene therapy; *angiogenesis; *peripheral
 occlusive artery disease--therapy--th
 collateral circulation; gene transfer; treatment outcome; symptomatology;
 gene expression; *limb* perfusion; angiography; *limb* salvage; edema
 --complication--co; blood vessel permeability; protein expression; protein
 analysis; human; male; female; clinical article; clinical trial; aged;
 adult; article; priority journal
 ?ds

Set	Items	Description
S1	25951	(THERAPEUTIC (W) ANGIOGENESIS) OR (NEOVASCULARIZATION)
S2	0	S1 AND (GM-CSF OR M-CSF OR G-CSF)
S3	86	S1 AND (SCF OR SDF-1 OR ANGIOPOIETIN-? OR FLT-3)
S4	10	S3 AND (IN (W) VIVO)
S5	9	RD (unique items)
S6	0	S1 AND ((IN (W) VIVO) AND B-FGF)
S7	0	(THERAPEUTIC (W) ANGIOGENESIS) AND (B-FGF)
S8	0	(GM-CSF) AND ((EPC) OR (ENDOTHELIAL (W) PROGENITOR?))
S9	13	(CSF) AND (EPC)
S10	8	RD (unique items)
S11	0	(ANGIOGENIC (W) (PEPTIDE OR POLYPEPTIDE)) AND (EPC)
S12	8	(THERAPEUTIC (W) ANGIOGENESIS) AND (ENDOTHELIAL (W) PROGEN- ITOR (W) CELL?)
S13	6	RD (unique items)
S14	434	(THERAPEUTIC (W) ANGIOGENESIS)
S15	267	S14 AND (ISCHEMIA)
S16	2	S15 AND (BRAIN)
S17	2	RD (unique items)
S18	0	S15 AND (CNS)
S19	187	S15 AND (LIMB OR HEART)
S20	116	RD (unique items)
S21	60	S20 NOT PY>1999
S22	0	S21 AND (CO-ADMINISTRATION OR CO-DELIVERY)
S23	2	S21 AND (ENDOTHELIAL (W) CELL (W) MITOGEN)
?s s21 and (CSF)		
	60	S21
	117103	CSF
S24	0	S21 AND (CSF)
?		
PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES		
?s (hematopoietic (w) factor) and (EPC)		
	95857	HEMATOPOIETIC
	1615552	FACTOR
	120	HEMATOPOIETIC (W) FACTOR
	1898	EPC
S25	0	(HEMATOPOIETIC (W) FACTOR) AND (EPC)
?s (hematopoietic (w) factor) and (endothelial (w) progenitor (w) cell)		
	95857	HEMATOPOIETIC
	1615552	FACTOR
	120	HEMATOPOIETIC (W) FACTOR
	232351	ENDOTHELIAL
	50136	PROGENITOR
	5352207	CELL
	24	ENDOTHELIAL (W) PROGENITOR (W) CELL
S26	0	(HEMATOPOIETIC (W) FACTOR) AND (ENDOTHELIAL (W) PROGENITOR (W) CELL)

?ds

Set	Items	Description
S1	25951	(THERAPEUTIC (W) ANGIOGENESIS) OR (NEOVASCULARIZATION)
S2	0	S1 AND (GM-CSF OR M-CSF OR G-CSF)
S3	86	S1 AND (SCF OR SDF-1 OR ANGIOPOIETIN-? OR FLT-3)
S4	10	S3 AND (IN (W) VIVO)

```

S5      9   RD (unique items)
S6      0   S1 AND ((IN (W) VIVO) AND B-FGF)
S7      0   (THERAPEUTIC (W) ANGIOGENESIS) AND (B-FGF)
S8      0   (GM-CSF) AND ((EPC) OR (ENDOTHELIAL (W) PROGENITOR?))
S9      13  (CSF) AND (EPC)
S10     8   RD (unique items)
S11     0   (ANGIOGENIC (W) (PEPTIDE OR POLYPEPTIDE)) AND (EPC)
S12     8   (THERAPEUTIC (W) ANGIOGENESIS) AND (ENDOTHELIAL (W) PROGEN-
        ITOR (W) CELL?)
S13     6   RD (unique items)
S14     434 (THERAPEUTIC (W) ANGIOGENESIS)
S15     267 S14 AND (ISCHEMIA)
S16     2   S15 AND (BRAIN)
S17     2   RD (unique items)
S18     0   S15 AND (CNS)
S19     187 S15 AND (LIMB OR HEART)
S20     116 RD (unique items)
S21     60  S20 NOT PY>1999
S22     0   S21 AND (CO-ADMINISTRATION OR CO-DELIVERY)
S23     2   S21 AND (ENDOTHELIAL (W) CELL (W) MITOGEN)
S24     0   S21 AND (CSF)
S25     0   (HEMATOPOIETIC (W) FACTOR) AND (EPC)
S26     0   (HEMATOPOIETIC (W) FACTOR) AND (ENDOTHELIAL (W) PROGENITOR
        (W) CELL)

```

?logoff

```

20apr01 07:59:56 User259876 Session D208.2
$10.66      3.332 DialUnits File155
$3.20      16 Type(s) in Format 3
$3.20      16 Types
$13.86 Estimated cost File155
$16.89      3.017 DialUnits File5
$11.55      7 Type(s) in Format 3
$11.55      7 Types
$28.44 Estimated cost File5
$29.80      3.506 DialUnits File73
$9.40       4 Type(s) in Format 3
$9.40       4 Types
$39.20 Estimated cost File73
OneSearch, 3 files, 9.854 DialUnits FileOS
$2.45 TYMNET
$83.95 Estimated cost this search
$84.39 Estimated total session cost 9.977 DialUnits

```

Status: Signed Off. (49 minutes)

Status: Path 1 of [Dialog Information Services via Modem]

Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 3106900061...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

***** HHHHHHHH SSSSSSSS?

Status: Signing onto Dialog

ENTER PASSWORD:

***** HHHHHHHH SSSSSSSS? *****

Welcome to DIALOG

Status: Connected

Dialog level 00.12.12D

Last logoff: 16apr01 09:05:17

Logon file001 20apr01 07:11:27

*** ANNOUNCEMENT ***

NEW FILE RELEASED

***IBISWorld Market Research (File 753)

***Investext PDF Index (File 745)

***Daily and Sunday Telegraph (London) Papers (File 756)

***The Mirror Group Publications (United Kingdom) (File 757)

***Reuters Business Insight (File 759)

UPDATING RESUMED

***Extel Financial Cards from Primark (File 500)

***Books In Print (File 470)

***Extel News Cards from Primark (File 501)

RELOADED

***Kompass Asia/Pacific (File 592)

***Kompass Central/Eastern Europe (File 593)

***Kompass Canada (File 594)

FILES REMOVED

***EconBase (File 565)

New pricing structure for Pharmaprojects (Files 128/928) from
April 1, 2001. Check Help News128 or Help News928 for further
information.

>>>Get immediate news with Dialog's First Release
news service. First Release updates major newswire
databases within 15 minutes of transmission over the
wire. First Release provides full Dialog searchability
and full-text features. To search First Release files in
OneSearch simply BEGIN FIRST for coverage from Dialog's
broad spectrum of news wires.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HILIGHT set on as '*'

File 1:ERIC 1966-2001/Apr 17
(c) format only 2001 The Dialog Corporation

Set	Items	Description
---	-----	-----

?b 155, 5, 73

20apr01 07:11:44 User259876 Session D208.1

\$0.43 0.123 DialUnits File1

\$0.43 Estimated cost File1

\$0.01 TYMNET

\$0.44 Estimated cost this search

\$0.44 Estimated total session cost 0.123 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2001/Apr W3

(c) format only 2000 Dialog Corporation

***File 155: Medline has now updated. For further information**

see Help News155.

File 5:Biosis Previews(R) 1969-2001/Apr W2

(c) 2001 BIOSIS

File 73:EMBASE 1974-2001/Apr W3

(c) 2001 Elsevier Science B.V.

***File 73: For information about Explode feature please**

see Help News73.

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

?s (therapeutic (w) angiogenesis) or (neovascularization)

	1605538	THERAPEUTIC
--	---------	-------------

	34478	ANGIOGENESIS
--	-------	--------------

	434	THERAPEUTIC(W)ANGIOGENESIS
--	-----	----------------------------

	25667	NEOVASCULARIZATION
--	-------	--------------------

S1	25951	(THERAPEUTIC (W) ANGIOGENESIS) OR (NEOVASCULARIZATION)
----	-------	--

?s s1 and (GM-CSF or M-CSF or G-CSF)

	25951	S1
--	-------	----

	746	GM-CSF
--	-----	--------

	72	M-CSF
--	----	-------

	339	G-CSF
--	-----	-------

S2	0	S1 AND (GM-CSF OR M-CSF OR G-CSF)
----	---	-----------------------------------

?s s1 and (SCF or SDF-1 or angiopoietin-? or Flt-3)

	25951	S1
--	-------	----

	6387	SCF
--	------	-----

	69	SDF-1
--	----	-------

	250	ANGIOPOIETIN-?
--	-----	----------------

	34	FLT-3
--	----	-------

S3	86	S1 AND (SCF OR SDF-1 OR ANGIOPOIETIN-? OR FLT-3)
----	----	--

?s s3 and (in (w) vivo)

Processing

Processing

Processing

Processing

	86	S3
--	----	----

	22997232	IN
--	----------	----

	850380	VIVO
--	--------	------

	828373	IN(W)VIVO
--	--------	-----------

S4	10	S3 AND (IN (W) VIVO)
----	----	----------------------

?rd

...completed examining records

S5	9	RD (unique items)
----	---	-------------------

?t s5/3,k/all

5/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

10753641 21101222

Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.

Stratmann A; Acker T; Burger AM; Amann K; Risau W; Plate KH

Department of Neuropathology, Freiburg University Medical School,

Freiburg, Germany.

International journal of cancer. Journal international du cancer (United States) Feb 1 2001, 91 (3) p273-82, ISSN 0020-7136 Journal Code: GQU

Languages: ENGLISH

Document type: Journal Article

... vascular endothelial growth factor (VEGF), a major regulator of embryonic and hypoxia-mediated angiogenesis, is necessary for tumor angiogenesis. VEGF is expressed in tumor cells *in vivo*, and its tyrosine kinase receptors VEGFR-1 and VEGFR-2 are up-regulated in the tumor endothelium. A second endothelial cell-specific ligand/receptor tyrosine...

... whereas M6378 tumors expressed VEGF, VEGFR-2, tie2 and angiopoietin-1 but little angiopoietin-2, suggesting activation of both VEGFR-2 and tie2 signaling pathways. *In vivo* studies using truncated dominant-negative tie2 and VEGFR-2 mutants revealed inhibition of M6363 tumor growth by 15% (truncated tie2) and 36% (truncated VEGFR-2...

Descriptors: Adenocarcinoma, Mucinous--blood supply--BS; *Breast Neoplasms--blood supply--BS; *Carcinoma, Infiltrating Duct--blood supply--BS; *Membrane Glycoproteins--metabolism--ME; *Neoplasm Proteins--metabolism--ME; **Neovascularization*, Pathologic--metabolism--ME; *Proteins--metabolism--ME; *Proto-Oncogene Proteins--metabolism--ME; *Receptor Protein-Tyrosine Kinases--metabolism--ME; *Receptors, Growth Factor--metabolism--ME

Chemical Name: Membrane Glycoproteins;Neoplasm Proteins;Proteins;Proto-Oncogene Proteins;RNA, Messenger;Receptors, Growth Factor;angiopoietin 2;*angiopoietin-1*; vascular endothelial cell growth factor receptor;proto-oncogene protein flt;TIE-2 receptor tyrosine kinase;Receptor Protein-Tyrosine Kinases

5/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

10730431 20580777

Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.

Fujiyama S; Matsubara H; Nozawa Y; Maruyama K; Mori Y; Tsutsumi Y; Masaki H; Uchiyama Y; Koyama Y; Nose A; Iba O; Tateishi E; Ogata N; Jyo N; Higashiyama S; Iwasaka T

Department of Medicine II, Kansai Medical University, Osaka, Japan.

Circulation research (UNITED STATES) Jan 19 2001, 88 (1) p22-9, ISSN 1524-4571 Journal Code: DCX

Languages: ENGLISH

Document type: Journal Article

... growth factor (VEGF) expression in an HB-EGF/EGFR-dependent manner. AT(2) inhibited AT(1)-mediated Ang2 expression and phosphorylation of EGFR. In an *in vivo* corneal assay, AT(1) induced angiogenesis in an HB-EGF-dependent manner and enhanced the angiogenic activity of VEGF. Although neither Ang2 nor Ang1 alone...

Descriptors: Endothelial Growth Factors--genetics--GE; *Epidermal Growth Factor--physiology--PH; *Lymphokines--genetics--GE; **Neovascularization*, Physiologic--physiology--PH; *Proteins--genetics--GE; *Receptor, Epidermal Growth Factor--genetics--GE; *Receptors, Angiotensin--physiology--PH...; drug effects--DE; Gene Expression Regulation--drug effects--DE; Imidazoles--pharmacology--PD; Indoles--pharmacology--PD; Maleimides--pharmacology--PD; Membrane Glycoproteins--genetics--GE; Naphthalenes--pharmacology--PD; *Neovascularization*, Physiologic--drug effects--DE; Protein Kinase C--antagonists and inhibitors--AI; Protein Kinase C--metabolism--ME; Protein-Tyrosine-Phosphatase--metabolism--ME; Pyridines--pharmacology--PD; RNA...

Chemical Name: CS 8; Endothelial Growth Factors; Imidazoles; Indoles; Lymphokines; Maleimides; Membrane Glycoproteins; Naphthalenes; Proteins; Pyridines; RNA, Messenger; Receptors, Angiotensin; Receptors, Cell Surface; Tetrazoles; Tyrphostins; angiopoietin 2; *angiopoietin-1*; angiotensin II type 1 receptor; angiotensin II type 2 receptor; vascular permeability factor; Angiotensin II; calphostin C; PD 123319; GF 109203X; heparin-binding EGF...

5/3,K/3 (Item 3 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

10697573 21012455

Early effects of hypoxia/reoxygenation on VEGF, ang-1, ang-2 and their receptors in the rat myocardium: implications for myocardial angiogenesis.

Ray PS; Estrada-Hernandez T; Sasaki H; Zhu L; Maulik N
Department of Surgery, University of Connecticut Health Center, Farmington, USA.

Molecular and cellular biochemistry (Netherlands) Oct 2000, 213 (1-2)
p145-53, ISSN 0300-8177 Journal Code: NGU
Contract/Grant No.: HL 22559, HL, NHLBI; HL 33889, HL, NHLBI; HL 56803, HL, NHLBI; +

Languages: ENGLISH

Document type: Journal Article

... Tie systems in adult rat myocardium. Western blot as well as immunohistochemical analyses were performed on hearts obtained from rats exposed to various durations of *in* *vivo* systemic hypoxemic hypoxia followed by 24 h reoxygenation. The relative time course of protein expression in response to increasing durations of hypoxia, as indicated from...

; Blotting, Western; Immunohistochemistry; *Neovascularization*, Physiologic; Rats; Rats, Sprague-Dawley

Chemical Name: Endothelial Growth Factors; Lymphokines; Membrane Glycoproteins; Proteins; Receptors, Cell Surface; angiopoietin 2; *angiopoietin-1*; vascular permeability factor; TIE-2 receptor tyrosine kinase; tie receptor tyrosine kinase; Receptor Protein-Tyrosine Kinases

5/3,K/4 (Item 4 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

10523859 20397756

A role for hematopoietic stem cells in promoting angiogenesis.

Takakura N; Watanabe T; Suenobu S; Yamada Y; Noda T; Ito Y; Satake M; Suda T

Department of Cell Differentiation, Institute of Molecular Embryology and Genetics, Kumamoto University School of Medicine, Japan.
ntakaku@gpo.kumamoto-u.ac.jp

Cell (UNITED STATES) Jul 21 2000, 102 (2) p199-209, ISSN 0092-8674
Journal Code: CQ4

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... Sp cultures from AML1 null embryos was rescued by addition of HSCs or angiopoietin-1 (Ang1). HSCs, which express Ang1, directly promoted migration of ECs *in* *vivo* and in vitro. These results indicate that HSCs are critical for angiogenesis.

Descriptors: Hematopoietic Stem Cells--Physiology--PH; *Neovascularization*, Physiologic--Physiology--PH

Chemical Name: Receptor Protein-Tyrosine Kinases; (*angiopoietin-1*; (menin; (vascular endothelial cell growth factor receptor; (Antigens, CD31; (AML1 protein; (DNA-Binding Proteins; (Membrane Glycoproteins; (Neoplasm Proteins; (Receptors, Growth Factor; (Transcription Factors

5/3,K/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

10110943 98373889

Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal *neovascularization* [see comments]

Asahara T; Chen D; Takahashi T; Fujikawa K; Kearney M; Magner M; Yancopoulos GD; Isner JM

Department of Medicine (Cardiology), St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass 02135, USA.

Circulation research (UNITED STATES) Aug 10 1998, 83 (3) p233-40,

ISSN 0009-7330 Journal Code: DAJ

Comment in Circ Res 1998 Aug 10;83(3):342-3

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal *neovascularization* [see comments]

... vessel formation in the developing embryo by antagonizing the effects of Ang1 and Tie2 and was thus considered to represent a natural Ang1/Tie2 inhibitor. *In* *vivo* effects of either angiopoietin on postnatal *neovascularization*, however, have not been previously described. Accordingly, we used the cornea micropocket assay of *neovascularization* to investigate the impact of angiopoietins on *neovascularization* *in* *vivo*. Neither Ang1 nor Ang2 alone promoted *neovascularization*. Pellets containing vascular endothelial growth factor (VEGF) alone induced corneal neovascularity extending from the limbus across the cornea. Addition of Ang 1 to VEGF (Ang1...

...more circumferential (160+/-15degrees) neovascularity than VEGF alone or Ang1+VEGF (P<0.05). Excess soluble Tie2 receptor (sTie2-Fc) precluded modulation of VEGF-induced *neovascularization* by both Ang2 and Ang1. Fluorescent microscopic findings demonstrated enhanced capillary density (fluorescence intensity, 2.55+/-0.23 e+9 versus 1.23+/-0.17...

... postnatal bioactivity associated with either angiopoietin. In particular, these results indicate that angiopoietins may potentiate the effects of other angiogenic cytokines. Moreover, these findings provide *in* *vivo* evidence that Ang1 promotes vascular network maturation, whereas Ang2 works to initiate *neovascularization*.

Descriptors: Endothelial Growth Factors--Metabolism--ME; *Lymphokines--Metabolism--ME; *Membrane Glycoproteins--Metabolism--ME; **Neovascularization*, Physiologic; *Proteins--Metabolism--ME; *Receptor Protein-Tyrosine Kinases--Metabolism--ME

Chemical Name: TIE-2 receptor tyrosine kinase; (Receptor Protein-Tyrosine Kinases; (angiopoietin 2; (*angiopoietin-1*; (vascular permeability factor; (Endothelial Growth Factors; (Enzyme Inhibitors; (Lymphokines; (Membrane Glycoproteins; (Proteins

5/3,K/6 (Item 6 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

10082440 97349327

Angiopoietin-2, a natural antagonist for Tie2 that disrupts *in* *vivo* angiogenesis [see comments]

Maisonpierre PC; Suri C; Jones PF; Bartunkova S; Wiegand SJ; Radziejewski C; Compton D; McClain J; Aldrich TH; Papadopoulos N; Daly TJ; Davis S; Sato TN; Yancopoulos GD

Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.

Science (UNITED STATES) Jul 4 1997, 277 (5322) p55-60, ISSN 0036-8075
Journal Code: UJ7

Comment in Science 19 Jul 4;277(5322):48-50

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Angiopoietin-2, a natural antagonist for Tie2 that disrupts *in* *vivo* angiogenesis [see comments]

Descriptors: Blood Vessels--Metabolism--ME; *Endothelium, Vascular
--Cytology--CY; **Neovascularization*, Physiologic; *Proteins--Metabolism
--ME; *Receptor Protein-Tyrosine Kinases--Antagonists and Inhibitors--AI

Chemical Name: TIE-2 receptor tyrosine kinase; (Receptor Protein-Tyrosine
Kinases; (angiopoietin 2; (*angiopoietin-1*; (vascular permeability factor;
(Endothelial Growth Factors; (Ligands; (Lymphokines; (Membrane
Glycoproteins; (Proteins; (Recombinant Fusion Proteins

5/3,K/7 (Item 7 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

08914063 97134664

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [see comments]

Suri C; Jones PF; Patan S; Bartunkova S; Maisonpierre PC; Davis S; Sato
TN; Yancopoulos GD

Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.

Cell (UNITED STATES) Dec 27 1996, 87 (7) p1171-80, ISSN 0092-8674

Journal Code: CQ4

Comment in Cell 1996 Dec 27;87(7):1153-5

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... reminiscent of those previously seen in mice lacking TIE2,
demonstrating that Angiopoietin-1 is a primary physiologic ligand for TIE2
and that it has critical *in* *vivo* angiogenic actions that are distinct
from VEGF and that are not reflected in the classic in vitro assays used to
characterize VEGF. Angiopoietin-1 seems...

Descriptors: Blood Vessels--Embryology--EM; *Endothelium, Vascular
--Embryology--EM; *Glycoproteins--Physiology--PH; *Membrane Glycoproteins
--Physiology--PH; **Neovascularization*, Physiologic; *Protein-Tyrosine
Kinase--Physiology--PH; *Proteins--Physiology--PH

Chemical Name: Protein-Tyrosine Kinase; (TIE-2 receptor tyrosine kinase;
(*angiopoietin-1*; (vascular permeability factor; (Endothelial Growth
Factors; (Glycoproteins; (Ligands; (Lymphokines; (Membrane Glycoproteins;
(Proteins; (RNA, Messenger

5/3,K/8 (Item 1 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

12777161 BIOSIS NO.: 200000530784

Expression and function of angiopoietin-1 in breast cancer.

AUTHOR: Hayes A J; Huang W-Q; Yu J; Maisonpierre P C; Liu A; Kern F G;
Lippman M E; McLeskey S W; Li L-Y(a)

AUTHOR ADDRESS: (a)Department of Oncology, Georgetown University Medical
Center, 3970 Reservoir Road, NW, RB/E301, Washington, DC, 20007**USA

JOURNAL: British Journal of Cancer 83 (9):p1154-1160 November, 2000

MEDIUM: print

ISSN: 0007-0920

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

...ABSTRACT: as an angiogenic promoter in embryonic angiogenesis by
promoting vascular branching, pericyte recruitment and endothelial

survival. We have investigated the role of Ang1 in tumor
 neovascularization under clinical conditions and in animal models. The
 expression of Ang1 in clinical breast cancer specimens was analysed by
 using laser-capture microdissection and reverse...
 ...REGISTRY NUMBERS: *ANGIOPOIETIN-1*
 DESCRIPTORS:
 ...ORGANISMS: human breast cancer cell line, *in*-*vivo* xenograft study
 ...
 CHEMICALS & BIOCHEMICALS: *angiopoietin-1*...

5/3,K/9 (Item 2 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2001 BIOSIS. All rts. reserv.

12777079 BIOSIS NO.: 200000530702
Expression of angiopoietin-1 and -2 and their receptor tie-2 in renal cell carcinoma.

AUTHOR: Theis H(a); Groene H-J(a); Rabelink T J
 AUTHOR ADDRESS: (a)Deutsches Krebsforschungszentrum, Heidelberg**Germany
 JOURNAL: Kidney & Blood Pressure Research 22 (4-6):p206 1999
 MEDIUM: print
 CONFERENCE/MEETING: Joint Scientific Meeting of the Society for Nephrology
 and the German Working Group for Clinical Nephrology Freiburg, Germany
 September 18-21, 1999
 ISSN: 1420-4096
 RECORD TYPE: Citation
 LANGUAGE: English
 SUMMARY LANGUAGE: English

...REGISTRY NUMBERS: *ANGIOPOIETIN-1*...

...*ANGIOPOIETIN-2*

DESCRIPTORS:

...ORGANISMS: PARTS ETC: circulatory system, *in* *vivo* examination...
 CHEMICALS & BIOCHEMICALS: ...*angiopoietin-1*...

...*angiopoietin-2*

MISCELLANEOUS TERMS: ...*neovascularization*;
 ?ds

Set	Items	Description
S1	25951	(THERAPEUTIC (W) ANGIOGENESIS) OR (NEOVASCULARIZATION)
S2	0	S1 AND (GM-CSF OR M-CSF OR G-CSF)
S3	86	S1 AND (SCF OR SDF-1 OR ANGIOPOIETIN-? OR FLT-3)
S4	10	S3 AND (IN (W) VIVO)
S5	9	RD (unique items)
?s s1 and ((in (w) vivo) and b-FGF)		
Processing		
Processing		
Processing		
	25951	S1
	22997232	IN
	850380	VIVO
	828373	IN(W)VIVO
	6	B-FGF
S6	0	S1 AND ((IN (W) VIVO) AND B-FGF)
?s (therapeutic (w) angiogenesis) and (b-FGF)		
	1605538	THERAPEUTIC
	34478	ANGIOGENESIS
	434	THERAPEUTIC(W)ANGIOGENESIS
	6	B-FGF
S7	0	(THERAPEUTIC (W) ANGIOGENESIS) AND (B-FGF)
?s (GM-CSF) and ((EPC) or (endothelial (w) progenitor?))		
	746	GM-CSF
	1898	EPC

232351 ENDOTHELIAL
 67508 PROGENITOR?
 136 ENDOTHELIAL(W)PROGENITOR?
 S8 0 (GM-CSF) AND ((EPC) OR (ENDOTHELIAL (W) PROGENITOR?))
 ?s (CSF) and (EPC)
 117103 CSF
 1898 EPC
 S9 13 (CSF) AND (EPC)
 ?rd
 ...completed examining records
 S10 8 RD (unique items)
 ?t s10/3,k/all

10/3,K/1 (Item 1 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2000 Dialog Corporation. All rts. reserv.

10659680 20526948

[Angiogenesis and vasculogenesis. Therapeutic strategies for stimulation of postnatal neovascularization]

Angiogenese und Vaskulogenese. Therapeutische Strategien zur Stimulation der postnatalen Neovaskularisation.

Kalka C; Asahara T; Krone W; Isner JM

Department of Medicine (Cardiovascular Research), Tufts University School of Medicine, St. Elizabeth's Medical Center, Boston, Massachusetts, USA.
 Ckalka@juno.com

Herz (GERMANY) Sep 2000, 25 (6) p611-22, ISSN 0340-9937
 Journal Code: F88

Languages: GERMAN

Document type: Journal Article; Review; Review, Tutorial

... new blood vessels from in situ differentiating endothelial cells. Recently considered to be restricted to embryogenesis, there exists now striking evidence that endothelial progenitor cells (*EPC*) circulate also in adult peripheral blood able to participate in ongoing neovascularization. Different cytokines and growth factors have a stimulatory effect on these bone-marrow derived *EPC*. Granulocyte macrophage colony stimulating factor (GM-*CSF*) and vascular endothelial growth factor (VEGF) mobilize *EPC* from the bone marrow into the peripheral circulation. While their endogenous contribution to postnatal neovascularization needs to be documented, the iatrogenic expansion and mobilization of *EPC* might represent an effective means to augment the resident population of endothelial cells (ECs). This kind of cell therapy for tissue regeneration in ischemic cardiovascular...

10/3,K/2 (Item 2 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2000 Dialog Corporation. All rts. reserv.

09862907 99217585

Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization.

Takahashi T; Kalka C; Masuda H; Chen D; Silver M; Kearney M; Magner M; Isner JM; Asahara T

Department of Medicine (Cardiology), St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02135-2997, USA.

Nature medicine (UNITED STATES) Apr 1999, 5 (4) p434-8, ISSN 1078-8956 Journal Code: CG5

Contract/Grant No.: HL 40518, HL, NHLBI; HL02824, HL, NHLBI; HL57516, HL, NHLBI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... into foci of neovascularization, consistent with postnatal vasculogenesis. We determined whether endogenous stimuli (tissue ischemia)

and exogenous cytokine therapy (granulocyte macrophage-colony stimulating factor, GM-CSF) mobilize EPCs and thereby contribute to neovascularization of ischemic tissues. The development of regional ischemia in both mice and rabbits increased the frequency of circulating EPCs. In mice, the effect of ischemia-induced *EPC* mobilization was demonstrated by enhanced ocular neovascularization after cornea micropocket surgery in mice with hindlimb ischemia compared with that in non-ischemic control mice. In rabbits with hindlimb ischemia, circulating EPCs were further augmented after pretreatment with GM-CSF, with a corresponding improvement in hindlimb neovascularization. There was direct evidence that EPCs that contributed to enhanced corneal neovascularization were specifically mobilized from the bone marrow in response to ischemia and GM-CSF in mice transplanted with bone marrow from transgenic donors expressing beta-galactosidase transcriptionally regulated by the endothelial cell-specific Tie-2 promoter. These findings indicate...

10/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

07479061 93074501

[Focal seizures in nonketotic hyperglycemia]

Crises focais na hiperglicemia nao cetotica.

Guerreiro CA; Falcao AE; Silveira DC

Departamento de Neurologia, Faculdade de Ciencias Medicas (FCM), Universidade Estadual de Campinas (UNICAMP), Brasil.

Arquivos de neuro-psiquiatria (BRAZIL) Dec 1991, 49 (4) p447-9, ISSN 0004-282X Journal Code: 8WY

Languages: PORTUGUESE Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE ; English Abstract

The cases of three patients with focal seizure associated to non-cetotic hyperglycemia are reported. Two patients presented motor epilepsy partialis continua (*EPC*). One case showed *EPC* as the first clinical manifestation of diabetes mellitus. Neurological exam was normal in all patients. CT and *CSF* were normal in the cases they were evaluated. Scalp EEG registered during a focal seizure revealed a bilateral temporal spiky activity. Glycemia levels were 455...

10/3,K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

07444796 91043403

***CSF* anomalies in children affected by Epilepsia Partialis Continua (*EPC*).**

Gaggero R; Ferraris PC; De Negri M

Istituto G. Gaslini, Universita di Genova, Italy.

Neuropediatrics (GERMANY) Aug 1990, 21 (3) p143-5, ISSN 0174-304X
Journal Code: NZA

Languages: ENGLISH

Document type: JOURNAL ARTICLE

***CSF* anomalies in children affected by Epilepsia Partialis Continua (*EPC*).**

In two children affected with "Epilepsia Partialis Continua" (*EPC*) of progressive type, probably secondary to a slow encephalitis, the percentage of T-lymphocytes in *CSF* was lower than normal (30% compared to 90%). The *CSF* T-lymphocytes are characterized by their ability to form E-rosettes. In one patient signs of intrathecal synthesis of IgG, especially oligoclonal bands at isoelectrofocusing, were observed. These results confirm, that in this type of *EPC* some immunological parameters in the *CSF* are impaired; so the aetiological hypothesis of an infectious disease, caused by a non-conventional viral agent, is supported.

10/3,K/5 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12763781 BIOSIS NO.: 200000517404
Angiogenesis and vasculogenesis. Therapeutic approaches for stimulation of post-natal neovascularization.
AUTHOR: Kalka Christoph(a); Asahara Takayuki; Krone Wilhelm; Isner Jeffrey M
AUTHOR ADDRESS: (a)Cardiovascular Research, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA, 02135**USA
JOURNAL: Herz 25 (6):p611-622 September, 2000
MEDIUM: print
ISSN: 0340-9937
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: German; Non-English
SUMMARY LANGUAGE: English; German

...ABSTRACT: new blood vessels from in situ differentiating endothelial cells. Recently considered to be restricted to embryogenesis, there exists now striking evidence that endothelial progenitor cells (*EPC*) circulate also in adult peripheral blood able to participate in ongoing neovascularization. Different cytokines and growth factors have a stimulatory effect on these bone-marrow derived *EPC*. Granulocyte macrophage colony stimulating factor (GM-*CSF*) and vascular endothelial growth factor (VEGF) mobilize *EPC* from the bone marrow into the peripheral circulation. While their endogenous contribution to postnatal neovascularization needs to be documented, the iatrogenic expansion and mobilization of *EPC* might represent an effective means to augment the resident population of endothelial cells (ECs). This kind of cell therapy for tissue regeneration in ischemic cardiovascular...

10/3,K/6 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12208667 BIOSIS NO.: 199900503516
Study on the mechanism of changes in N-linked sugar chain structure of erythroid progenitor cells surface in vitamin A deficiency rats.
AUTHOR: Feng Tao(a); Li Tingyu(a); Wang Yaping(a); Liu Yu(a); Qu Ping(a); Jiang Rong(a)
AUTHOR ADDRESS: (a)Department of Biochemistry, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400046**China
JOURNAL: Acta Nutrimenta Sinica 21 (1):p13-17 June, 1999
ISSN: 0512-7955
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Chinese; Non-English
SUMMARY LANGUAGE: Chinese; English

ABSTRACT: Objective: To clarify the mechanism of abnormality of N-linked sugar chain structure of erythroid progenitor cells (*EPC*) caused by vitamin A deficiency (VAD). Method: Effects of bone marrow stromal cell media (BMSCM) and spleen cell media (SCM) from VAD rats on the N-linked sugar chain structure of *EPC* surface in normal rats were investigated by 3H-Mannose (3H-Man) incorporation, serial lectin affinity chromatography and gelfiltration combined with exoglycosidase treatment. Results: The results showed that BMSCM and SCM from VAD rats: (1) decreased 3H-Man incorporation into N-glycopeptide on *EPC* surface; (2) decreased the percentage of complex type and increased the percentages of high mannose and hybrid type; (3) in complex type, declined the percentages...

...or B-Gn and C-Fuc. Conclusion: It is suggested that VAD can affect the expression/activity of hematopoietic growth factors, IL-3 and GM-*CSF*, and therefore lead to abnormality of N-sugar chains of *EPC* surface and proliferation of *EPC*.

10/3,K/7 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

06717452 BIOSIS NO.: 000088026878

EFFECTS OF LYMPHOKINES AND IMMUNE COMPLEXES ON MURINE PLACENTAL CELL GROWTH IN-VITRO

AUTHOR: ARMSTRONG D T; CHAOUAT G
AUTHOR ADDRESS: DEP. OBSTET. GYNAECOL., 9-OF10, UNIV. HOSP. LONDON,
ONTARIO, CANADA N6A 5A5.

JOURNAL: BIOL REPROD 40 (3). 1989. 466-474. 1989

FULL JOURNAL NAME: Biology of Reproduction

CODEN: BIREB

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

...ABSTRACT: absence or presence of ConA-conditioned medium. In contrast to late-gestational stage placental cells, cell suspensions obtained from Days 8-9 murine ectoplacental cone (*EPC*) outgrowths, or from earlier stage placentas (Day 12-14) responded to low concentrations of conditioned medium from ConA-stimulated splenocytes with increased proliferation. The effect...

...impressive on placental cells at gestational ages later than 12 days than on earlier stage preparations. On all placental cell suspensions tested, as well as *EPC* cells, a clear-cut inhibition of growth was observed at high doses of conditioned medium. To rule out a direct role of ConA on placental...

...yielding similar data. Partially purified rat interleukin-2 (IL-2) did not stimulate placental growth in vitro, whereas purified granulocyte-macrophage colony-stimulating factor (GM-*CSF*) was active on both *EPC* and mature placental cells. The results of these experiments support an "immunotrophic" role of maternal lymphocytes in enhancing placental growth in allogeneically pregnant mice, but...

...probably are not mediated by direct effects on placental cells. They also confirm that one of the active T cell lymphokines is most probably GM-*CSF*, and suggest that the age or differentiation state of placenta is involved in the pattern of the response to immunotrophic stimuli.

10/3,K/8 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

04865848 EMBASE No: 1992006063

Partial seizures in non-cetotic hyperglycemia

CRISES FOCAIS NA HIPERGLICEMIA NAO CETOTICA

Guerreiro C.A.M.; Falcao A.E.; Silveira D.C.

Departamento de Neurologia, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Caixa Postal 6111, 13081 Campinas SP Brazil

Arquivos de Neuro-Psiquiatria (ARQ. NEURO-PSIQUIATR.) (Brazil) 1991, 49/4 (447-449)

CODEN: ANPIA ISSN: 0004-282X

DOCUMENT TYPE: Journal; Article

LANGUAGE: PORTUGUESE SUMMARY LANGUAGE: PORTUGUESE; ENGLISH

The cases of three patients with focal seizure associated to non-cetotic

hyperglycemia are reported. Two patients presented motor epilepsy partialis continua (*EPC*). One case showed *EPC* as the first clinical manifestation of diabetes mellitus. Neurological exam was normal in all patients. CT and *CSF* were normal in the cases they were evaluated. Scalp EEG registered during a focal seizure revealed a bilateral temporal spiky activity. Glycemia levels were 455...
 ?ds

Set	Items	Description
S1	25951	(THERAPEUTIC (W) ANGIOGENESIS) OR (NEOVASCULARIZATION)
S2	0	S1 AND (GM-CSF OR M-CSF OR G-CSF)
S3	86	S1 AND (SCF OR SDF-1 OR ANGIOPOIETIN-? OR FLT-3)
S4	10	S3 AND (IN (W) VIVO)
S5	9	RD (unique items)
S6	0	S1 AND ((IN (W) VIVO) AND B-FGF)
S7	0	(THERAPEUTIC (W) ANGIOGENESIS) AND (B-FGF)
S8	0	(GM-CSF) AND ((EPC) OR (ENDOTHELIAL (W) PROGENITOR?))
S9	13	(CSF) AND (EPC)
S10	8	RD (unique items)
?s (angiogenic (w) (peptide or polypeptide)) and (EPC)		
	13078	ANGIOGENIC
	561839	PEPTIDE
	180009	POLYPEPTIDE
	193	ANGIOGENIC(W) (PEPTIDE OR POLYPEPTIDE)
	1898	EPC
S11	0	(ANGIOGENIC (W) (PEPTIDE OR POLYPEPTIDE)) AND (EPC)
?s (therapeutic (w) angiogenesis) and (endothelial (w) progenitor (w) cell?)		
Processing		
	1605538	THERAPEUTIC
	34478	ANGIOGENESIS
	434	THERAPEUTIC(W)ANGIOGENESIS
	232351	ENDOTHELIAL
	50136	PROGENITOR
	6903151	CELL?
	107	ENDOTHELIAL(W)PROGENITOR(W)CELL?
S12	8	(THERAPEUTIC (W) ANGIOGENESIS) AND (ENDOTHELIAL (W) PROGENITOR (W) CELL?)

?rd

...completed examining records

S13 6 RD (unique items)

?t s13/3,k/all

13/3,K/1 (Item 1 from file: 155)
 DIALOG(R)File 155:MEDLINE(R)
 (c) format only 2000 Dialog Corporation. All rts. reserv.

10831398 21103748

***Therapeutic* *angiogenesis* for ischemic cardiovascular disease.**

Freedman S; Isner JM

Divisions of Cardiology and Vascular Medicine, Tufts University School of Medicine, Boston, MA, USA

Journal of molecular and cellular cardiology (England) Mar 2001, 33

(3) p379-93, ISSN 0022-2828 Journal Code: J72

Languages: ENGLISH

Document type: Journal Article

***Therapeutic* *angiogenesis* for ischemic cardiovascular disease.**

... activity, the best studied both in animal models and clinical trials are vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Clinical trials of *therapeutic* *angiogenesis* in patients with end-stage coronary artery disease have shown large increases in exercise time and marked reductions in symptoms of angina, as well as...

... clinical studies will be required to determine the optimal dose, formulation, route of administration and combinations of growth factors, as well as the requirement for *endothelial* *progenitor* *cell* or stem cell

supplementation, to provide effective and safe therapeutic myocardial angiogenesis. Copyright 2001 Academic Press.

13/3,K/2 (Item 2 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

10659690 20526948

[Angiogenesis and vasculogenesis. Therapeutic strategies for stimulation of postnatal neovascularization]

Angiogenese und Vaskulogenese. Therapeutische Strategien zur Stimulation der postnatalen Neovaskularisation.

Kalka C; Asahara T; Krone W; Isner JM

Department of Medicine (Cardiovascular Research), Tufts University School of Medicine, St. Elizabeth's Medical Center, Boston, Massachusetts, USA.
Ckalka@juno.com

Herz (GERMANY) Sep 2000, 25 (6) p611-22, ISSN 0340-9937
Journal Code: F88

Languages: GERMAN

Document type: Journal Article; Review; Review, Tutorial

...and adult organism. While pathologic angiogenesis includes the role of post-natal neovascularization in the pathogenesis of arthritis, diabetic retinopathy, and tumor growth and metastasis, *therapeutic* *angiogenesis*, either endogenously or in response to administered growth factors, includes the development of collateral blood vessels in tissue ischemia. Preclinical studies established that angiogenic growth...

... the development of new blood vessels from in situ differentiating endothelial cells. Recently considered to be restricted to embryogenesis, there exists now striking evidence that *endothelial* *progenitor* *cells* (EPC) circulate also in adult peripheral blood able to participate in ongoing neovascularization. Different cytokines and growth factors have a stimulatory effect on these bone...

13/3,K/3 (Item 3 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

09986916 99301984

Vascular endothelial factor (VEGF): *therapeutic* *angiogenesis* and vasculogenesis in the treatment of cardiovascular disease]

Vaskularer endothelialer Wachstumsfaktor (VEGF): Therapeutische Angiogenese und Vaskulogenese in der Behandlung kardiovaskularer Erkrankungen.

Kalka C; Takahashi T; Masuda H; Asahara T; Isner JM

Department of Vascular Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA.

Medizinische Klinik (GERMANY) Apr 15 1999, 94 (4) p193-201, ISSN 0723-5003 Journal Code: M9K

Languages: GERMAN Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL ; English Abstract

Vascular endothelial factor (VEGF): *therapeutic* *angiogenesis* and vasculogenesis in the treatment of cardiovascular disease]

... development of new blood vessels from in situ differentiating endothelial cells, has been previously considered restricted to embryogenesis. Recent investigations, however, show the existence of *endothelial* *progenitor* *cells* (EPCs) in the peripheral blood of the adult and their participation in ongoing neovascularization. Molecular and cell-biological experiments suggest that different cytokines and growth...

13/3,K/4 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12953925 BIOSIS NO.: 200100161074

***Therapeutic* *angiogenesis* by bone marrow-derived cell transplantation in pigs with coronary constrictor-induced chronic myocardial ischemia.**

AUTHOR: Ueno Takafumi(a); Coussement Patrick K; Murohara Toyoaki; Cui Jianhua; Fallahi Payam; Ueno Mika; Frohwein Stephen; Baldwin Samuel; Palasis Maria; Imaizumi Tsutomu; Chronos Nicolas A F; Robinson Keith A
AUTHOR ADDRESS: (a)Atlanta Cardiovascular Research Institute, Norcross, GA
**USA

JOURNAL: Journal of the American College of Cardiology 37 (2 Supplement A):p48A February, 2001

MEDIUM: print

CONFERENCE/MEETING: 50th Annual Scientific Session of the American College of Cardiology Orlando, Florida, USA March 18-21, 2001

ISSN: 0735-1097

RECORD TYPE: Citation

LANGUAGE: English

SUMMARY LANGUAGE: English

***Therapeutic* *angiogenesis* by bone marrow-derived cell transplantation in pigs with coronary constrictor-induced chronic myocardial ischemia.**

DESCRIPTORS:

...ORGANISMS: PARTS ETC: *endothelial* *progenitor* *cells*;

MISCELLANEOUS TERMS: *therapeutic* *angiogenesis*;

13/3,K/5 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12763781 BIOSIS NO.: 200000517404

Angiogenesis and vasculogenesis. Therapeutic approaches for stimulation of post-natal neovascularization.

AUTHOR: Kalka Christoph(a); Asahara Takayuki; Krone Wilhelm; Isner Jeffrey
M

AUTHOR ADDRESS: (a)Cardiovascular Research, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA, 02135**USA

JOURNAL: Herz 25 (6):p611-622 September, 2000

MEDIUM: print

ISSN: 0340-9937

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: German; Non-English

SUMMARY LANGUAGE: English; German

...ABSTRACT: and adult organism. While pathologic angiogenesis includes the role of post-natal neovascularization in the pathogenesis of arthritis, diabetic retinopathy, and tumor growth and metastasis, *therapeutic* *angiogenesis*, either endogenously or in response to administered growth factors, includes the development of collateral blood vessels in tissue ischemia. Preclinical studies established that angiogenic growth...
...the development of new blood vessels from in situ differentiating endothelial cells. Recently considered to be restricted to embryogenesis, there exists now striking evidence that *endothelial* *progenitor* *cells* (EPC) circulate also in adult peripheral blood able to participate in ongoing neovascularization. Different cytokines and growth factors have a stimulatory effect on these bone...

13/3,K/6 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

07678437 EMBASE No: 1999161673

**Vascular endothelial growth factor (VEGF): *Therapeutic* *angiogenesis*
and vasculogenesis in the treatment of cardiovascular disease**
VASKULÄRER ENDOTHELIALER WACHSTUMSFAKTOR (VEGF): THERAPEUTISCHE
ANGIOGENESE UND VASKULOGENESE IN DER BEHANDLUNG KARDIOVASKULÄRER
ERKRANKUNGEN

Kalka C.; Takahashi T.; Masuda H.; Asahara T.; Isner J.M.
Dr. C. Kalka, Department of Vascular Medicine, St. Elizabeth's Medical
Center, Tufts University School of Medicine, 736 Cambridge Street,
Boston, MA 02135 United States
Medizinische Klinik (MED. KLIN.) (Germany) 15 APR 1999, 94/4 (193-201)
CODEN: MEKLA ISSN: 0723-5003
DOCUMENT TYPE: Journal; Review
LANGUAGE: GERMAN SUMMARY LANGUAGE: ENGLISH; GERMAN
NUMBER OF REFERENCES: 89

**Vascular endothelial growth factor (VEGF): *Therapeutic* *angiogenesis*
and vasculogenesis in the treatment of cardiovascular disease**

...development of new blood vessels from in situ differentiating
endothelial cells, has been previously considered restricted to
embryogenesis. Recent investigations, however, show the existence of
endothelial *progenitor* *cells* (EPCs) in the peripheral blood of the
adult and their participation in ongoing neovascularization. Molecular and
cell-biological experiments suggest that different cytokines and growth...
?ds

Set	Items	Description
S1	25951	(THERAPEUTIC (W) ANGIOGENESIS) OR (NEOVASCULARIZATION)
S2	0	S1 AND (GM-CSF OR M-CSF OR G-CSF)
S3	86	S1 AND (SCF OR SDF-1 OR ANGIOPOIETIN-? OR FLT-3)
S4	10	S3 AND (IN (W) VIVO)
S5	9	RD (unique items)
S6	0	S1 AND ((IN (W) VIVO) AND B-FGF)
S7	0	(THERAPEUTIC (W) ANGIOGENESIS) AND (B-FGF)
S8	0	(GM-CSF) AND ((EPC) OR (ENDOTHELIAL (W) PROGENITOR?))
S9	13	(CSF) AND (EPC)
S10	8	RD (unique items)
S11	0	(ANGIOGENIC (W) (PEPTIDE OR POLYPEPTIDE)) AND (EPC)
S12	8	(THERAPEUTIC (W) ANGIOGENESIS) AND (ENDOTHELIAL (W) PROGEN- ITOR (W) CELL?)
S13	6	RD (unique items)
?s (therapeutic (w) angiogenesis)		
	1605538	THERAPEUTIC
	34478	ANGIOGENESIS
S14	434	(THERAPEUTIC (W) ANGIOGENESIS)
?s s14 and (ischemia)		
	434	S14
	271117	ISCHEMIA
S15	267	S14 AND (ISCHEMIA)
?s s15 and (brain)		
	267	S15
	1318088	BRAIN
S16	2	S15 AND (BRAIN)
?rd		
...completed examining records		
S17	2	RD (unique items)
?t s17/3,k/all		

17/3,K/1 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

10570996 20332856

Electromagnetic *therapeutic* *angiogenesis*: the next step.

Cuevas P; Asin-Cardiel E
Departamento de Investigacion, Hospital Ramon y Cajal, Madrid, Spain.

pedro.cuevas@hrc.es
 Neurological research (ENGLAND) Jun 2000, 22 (4) p349-50, ISSN
 0161-6412 Journal Code: NY9
 Languages: ENGLISH
 Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

Electromagnetic *therapeutic* *angiogenesis*: the next step.

Therapeutic *angiogenesis*, in the form of growth factor protein administration or gene therapy, is a new method of treatment for patients with severe coronary and peripheral artery...

Descriptors: *Brain* *Ischemia*--Therapy--TH; *Cerebral Revascularization
 --Methods--MT; *Cerebral Revascularization--Trends--TD; *Electric
 Stimulation Therapy--Trends--TD; *Neovascularization, Physiologic

17/3,K/2 (Item 1 from file: 73)
 DIALOG(R)File 73:EMBASE
 (c) 2001 Elsevier Science B.V. All rts. reserv.

05841197 EMBASE No: 1994260327

Angiogenesis: Potential therapy for ischaemic disease

Symes J.F.; Sniderman A.D.

Division of Cardiothoracic Surgery, Department of Surgery, St Elizabeth's
 Medical Center, 736 Cambridge Street, Boston, MA 02135 United States

Current Opinion in Lipidology (CURR. OPIN. LIPIDOLOGY) (United Kingdom)
 1994, 5/4 (305-312)

CODEN: COPL ISSN: 0957-9672

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...various exogenous angiogenic agents by several routes has resulted in
 enhanced growth of collateral vessels in animal models of myocardial,
 peripheral arterial, and cerebral insufficiency. *Therapeutic*
 angiogenesis may have an immense clinical potential.

MEDICAL DESCRIPTORS:

*angiogenesis; **ischemia*--drug therapy--dt
 animal cell; animal experiment; animal model; *brain* *ischemia*--drug
 therapy--dt; collateral circulation; controlled study; heart muscle
 ischemia--drug therapy--dt; intraarticular drug administration;
 intramuscular drug administration; leg *ischemia*--drug therapy--dt; leg
 revascularization; necrosis; nonhuman; priority journal; rat; review;
 subcutaneous drug administration; topical drug administration
 ?ds

Set	Items	Description
S1	25951	(THERAPEUTIC (W) ANGIOGENESIS) OR (NEOVASCULARIZATION)
S2	0	S1 AND (GM-CSF OR M-CSF OR G-CSF)
S3	86	S1 AND (SCF OR SDF-1 OR ANGIOPOIETIN-? OR FLT-3)
S4	10	S3 AND (IN (W) VIVO)
S5	9	RD (unique items)
S6	0	S1 AND ((IN (W) VIVO) AND B-FGF)
S7	0	(THERAPEUTIC (W) ANGIOGENESIS) AND (B-FGF)
S8	0	(GM-CSF) AND ((EPC) OR (ENDOTHELIAL (W) PROGENITOR?))
S9	13	(CSF) AND (EPC)
S10	8	RD (unique items)
S11	0	(ANGIOGENIC (W) (PEPTIDE OR POLYPEPTIDE)) AND (EPC)
S12	8	(THERAPEUTIC (W) ANGIOGENESIS) AND (ENDOTHELIAL (W) PROGEN- ITOR (W) CELL?)
S13	6	RD (unique items)
S14	434	(THERAPEUTIC (W) ANGIOGENESIS)
S15	267	S14 AND (ISCHEMIA)
S16	2	S15 AND (BRAIN)
S17	2	RD (unique items)
?s s15 and (CNS)		
	267	S15
	108636	CNS

S18 0 S15 AND (CNS)
 ?s s15 and (limb or heart)
 267 S15
 129572 LIMB
 1471140 HEART
 S19 187 S15 AND (LIMB OR HEART)
 ?rd
 ...examined 50 records (50)
 ...examined 50 records (100)
 ...examined 50 records (150)
 ...completed examining records
 S20 116 RD (unique items)
 ?s s20 not py>1999
 116 S20
 1629129 PY>1999
 S21 60 S20 NOT PY>1999
 ?s s21 and (co-administration or co-delivery)
 60 S21
 46 CO-ADMINISTRATION
 2 CO-DELIVERY
 S22 0 S21 AND (CO-ADMINISTRATION OR CO-DELIVERY)
 ?s s21 and (endothelial (w) cell (w) mitogen)
 60 S21
 232351 ENDOTHELIAL
 5352207 CELL
 91415 MITOGEN
 344 ENDOTHELIAL(W)CELL(W)MITOGEN
 S23 2 S21 AND (ENDOTHELIAL (W) CELL (W) MITOGEN)
 ?t s23/3,k/all

23/3,K/1 (Item 1 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2000 Dialog Corporation. All rts. reserv.

09447397 98196682
Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical *limb* *ischemia* [see comments]
 Baumgartner I; Pieczek A; Manor O; Blair R; Kearney M; Walsh K; Isner JM
 Department of Medicine (Cardiology), St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass 02135, USA.
 Circulation (UNITED STATES) Mar 31 1998, 97 (12) p1114-23, ISSN 0009-7322 Journal Code: DAW
 Contract/Grant No.: HL-02824, HL, NHLBI; HL-53354, HL, NHLBI; HL-57516, HL, NHLBI; +
 Comment in Circulation 1998 Mar 31;97(12):1108-10; Comment in: Circulation 1999 Jun 8;99(22):2967-8
 Languages: ENGLISH
 Document type: JOURNAL ARTICLE

Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical *limb* *ischemia* [see comments]

BACKGROUND: Preclinical studies have indicated that angiogenic growth factors can stimulate the development of collateral arteries, a concept called "*therapeutic* *angiogenesis* ." The objectives of this phase 1 clinical trial were (1) to document the safety and feasibility of intramuscular gene transfer by use of naked plasmid DNA encoding an *endothelial* *cell* *mitogen* and (2) to analyze potential therapeutic benefits in patients with critical *limb* *ischemia*. METHODS AND RESULTS: Gene transfer was performed in 10 limbs of 9 patients with nonhealing ischemic ulcers (n=7/10) and/or rest pain (n...

... naked plasmid DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (phVEGF165) was injected directly into the muscles of the ischemic *limb* . Gene expression was documented by a

transient increase in serum levels of VEGF monitored by ELISA. The ankle-brachial index improved significantly (0.33+/-0...

... resonance angiography showed qualitative evidence of improved distal flow in 8 limbs. Ischemic ulcers healed or markedly improved in 4 of 7 limbs, including successful *limb* salvage in 3 patients recommended for below-knee amputation. Tissue specimens obtained from an amputee 10 weeks after gene therapy showed foci of proliferating endothelial...

... permeability. CONCLUSIONS: These findings may be cautiously interpreted to indicate that intramuscular injection of naked plasmid DNA achieves constitutive overexpression of VEGF sufficient to induce *therapeutic* *angiogenesis* in selected patients with critical *limb* *ischemia*.

Descriptors: Collateral Circulation--Genetics--GE; *Endothelial Growth Factors--Genetics--GE; *Gene Transfer; **Ischemia*--Therapy--TH; *Lymphokines--Genetics--GE; *Plasmids

23/3,K/2 (Item 1 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2001 Elsevier Science B.V. All rts. reserv.

07224358 EMBASE No: 1998110133

Constitutive expression of phVEGF_{inf} 1inf 6SD5 after intramuscular gene transfer promotes collateral vessel development in patients with critical *limb* *ischemia*

Baumgartner I.; Pieczek A.; Manor O.; Blair R.; Kearney M.; Walsh K.;

Isner J.M.

Dr. J.M. Isner, St Elizabeth's Medical Center, 736 Cambridge St, Boston, MA 02135 United States

AUTHOR EMAIL: jisner@opal.tufts.edu

Circulation (CIRCULATION) (United States) 31 MAR 1998, 97/12

(1114-1123)

CODEN: CIRCA ISSN: 0009-7322

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 59

Constitutive expression of phVEGF_{inf} 1inf 6SD5 after intramuscular gene transfer promotes collateral vessel development in patients with critical *limb* *ischemia*

Background - Preclinical studies have indicated that angiogenic growth factors can stimulate the development of collateral arteries, a concept called '*therapeutic* *angiogenesis*.' The objectives of this phase 1 clinical trial were (1) to document the safety and feasibility of intramuscular gene transfer by use of naked plasmid DNA encoding an *endothelial* *cell* *mitogen* and (2) to analyze potential therapeutic benefits in patients with critical *limb* *ischemia*. Methods and Results - Gene transfer was performed in 10 limbs of 9 patients with nonhealing ischemic ulcers (n=7/10) and/or rest pain (n...

...encoding the 165-amino-acid isoform of human vascular endothelial growth factor (phVEGF_{inf} 1inf 6SD5) was injected directly into the muscles of the ischemic *limb*. Gene expression was documented by a transient increase in serum levels of VEGF monitored by ELISA. The ankle-brachial index improved significantly (0.33+/-0...

...resonance angiography showed qualitative evidence of improved distal flow in 8 limbs. Ischemic ulcers healed or markedly improved in 4 of 7 limbs, including successful *limb* salvage in 3 patients recommended for below-knee amputation. Tissue specimens obtained from an amputee 10 weeks after gene therapy showed foci of proliferating endothelial...

...permeability. Conclusions - These findings may be cautiously interpreted to indicate that intramuscular injection of naked plasmid DNA achieves